The Expert Committee recommended the inclusion of nicotine lozenges and mouth spray on the core list of the EML as additional forms of nicotine replacement therapy for tobacco and smoking cessation. The Committee noted high-quality evidence from multiple randomized controlled trials that all licensed forms of nicotine replacement therapy are effective at increasing increase cessation rates. The Committee considered that the availability of different forms of nicotine replacement therapy would provide options and choice for patients and clinicians, and could facilitate increased market competition, reduce costs and improve affordable access for national health systems.